NasdaqGS:REGNBiotechs
How Dupixent’s New Pediatric Asthma Nod in Japan Will Impact Regeneron Pharmaceuticals (REGN) Investors
Regeneron Pharmaceuticals and Sanofi previously announced that Japan’s Ministry of Health, Labour and Welfare granted marketing and manufacturing authorization for Dupixent (dupilumab) to treat severe or refractory bronchial asthma in children aged 6 to 11 whose symptoms are not adequately controlled with existing therapies.
This pediatric asthma approval in a major market broadens Dupixent’s eligible patient pool and highlights the drug’s expanding role across allergic and inflammatory...